UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination with Continuous or Intermittent CTEP-Supplied Agent ABT-888 (NSC #737664, IND #77840) and CTEP-Supplied Agent Bevacizumab (NSC #704865, IND #7921) and in Newly Diagnosed Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Participants in this study have been newly diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The purpose of the study is to test the safety of the drug, ABT-888, at different dose levels. Approximately 10 women will take part in this study conducted by investigators at the University of Iowa.

Start Date
February 16, 2010
End Date
February 16, 2020
Gender Preference
Age Group
18 - 99 years
Principal Investigator
David Bender, MD
Contact Info

Lynn Schaul, 319-384-6076

ABT-888 ; cancer ; de geest ; epithelial ovarian cancer ; fallopian tube cancer ; GOG #9923 ; phase I ; phase one ; primary peritoneal cancer ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.